Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Serotonin (
5-hydroxytryptamine
, 5-HT) may play an important role in the pathogenesis of
schizophrenia
. Previous studies suggested that the efficacy of atypical neuroleptic drugs (e.g., risperidone and clozapine) on negative symptoms may be related to the 5-HT2a receptor. Although association studies between MspI polymorphism (T102C) and the 5-HT2a receptor gene and
schizophrenia
have been reported, their results are still controversial. The aim of this study was to examine the association between T102C polymorphism of the 5-HT2a receptor gene and
schizophrenia
as well as the association between the polymorphism and negative symptoms in a Japanese population (106 patients with
schizophrenia
and 109 healthy controls). No significant positive associations were observed. Our results suggest that the 5-HT2a receptor gene is not involved in the pathogenesis of
schizophrenia
or negative symptoms.
...
PMID:Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan. 969 52
1. Sex steroid hormones exert profound effects on mood and mental state. Thus, in women, oestrogen is thought to protect against depression and delay the onset of
schizophrenia
and Alzheimer's disease. 2. Our studies in the female rat show that oestradiol, in its positive feedback mode for gonadotrophin release, increases the expression of genes for the
5-hydroxytryptamine
5-HT2A receptor and the serotonin transporter (SERT) in the dorsal raphe nucleus and the density of 5-HT2A receptor and SERT sites in regions of the forebrain that, in the human, are concerned with cognition, mental state, emotion and memory. 3. In the male rat, castration decreases while oestrogen and testosterone, but not 5 alpha-dihydrotestosterone (5 alpha-DHT), increase the density of 5-HT2A receptors in forebrain. The fact that 5 alpha-DHT has no effect suggests that the action of testosterone depends on its conversion to oestradiol by aromatase. 4. In intact rats, the density of 5-HT2A receptors in cerebral cortex is significantly higher in pro-oestrous female than in male and dioestrous female rats, showing that the spontaneous, preovulatory surge of oestradiol that reaches a peak at 12.00 h of pro-oestrus also increases the density of 5-HT2A receptors in cortex. 5. Oestrogen and testosterone (by way of its conversion to oestrogen) also stimulate the expression of the arginine vasopressin gene in the bed nucleus of the stria terminalis of the rodent, a mechanism that plays a key role in olfactory memory. 6. These actions of sex steroid hormones are discussed in the context of genomic versus non-genomic mechanisms, the recent discovery that there are two oestradiol receptors with different distributions in brain, the significance of our findings for our understanding of the control of mood, mental state and memory and the mechanism by which oestrogen stimulation of the 5-HT2A receptor could delay the onset of Alzheimer's disease.
...
PMID:Sex steroid control of mood, mental state and memory. 978 14
The A(-1438)G promoter polymorphism of the
5-hydroxytryptamine
2a receptor (5-HT2AR) gene and its influence on the cortical density of 5-HT2AR was studied using brain tissue donated at autopsy from 58 schizophrenic and 64 non-schizophrenic subjects. A linkage between genotypes for the A(-1438)G and a T102C polymorphic site identified in a previous study was observed. Our data suggest no association of the A(-1438)G polymorphism with
schizophrenia
and no effect of the promoter genotype upon 5-HT2AR densities in either the schizophrenic or non-schizophrenic groups.
...
PMID:No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. 1007 31
Serotonergic (
5-hydroxytryptamine
; 5-HT) transmission may play an important role in the treatment and/or pathogenesis of
schizophrenia
. Previous studies reported that several atypical antipsychotic agents have high affinities for the 5-HT6 receptor. The 5-HT6 receptor gene polymorphism might contribute to the genetic background of this disorder. One hundred and fifty unrelated patients with
schizophrenia
and 150 unrelated healthy controls were genotyped for a biallelic polymorphism (267C/T) at the 5-HT6 receptor gene. No significant positive association between the 5-HT6 receptor genotype and
schizophrenia
was observed. Our results suggests that the 267C/T polymorphism of the 5-HT6 receptor gene may not be involved in the susceptibility to
schizophrenia
.
...
PMID:Association study of the 5-HT6 receptor gene in schizophrenia. 1020 28
Despite a hundred years' research, the neuropathology of
schizophrenia
remains obscure. However, neither can the null hypothesis be sustained--that it is a 'functional' psychosis, a disorder with no structural basis. A number of abnormalities have been identified and confirmed by meta-analysis, including ventricular enlargement and decreased cerebral (cortical and hippocampal) volume. These are characteristic of
schizophrenia
as a whole, rather than being restricted to a subtype, and are present in first-episode, unmedicated patients. There is considerable evidence for preferential involvement of the temporal lobe and moderate evidence for an alteration in normal cerebral asymmetries. There are several candidates for the histological and molecular correlates of the macroscopic features. The probable proximal explanation for decreased cortical volume is reduced neuropil and neuronal size, rather than a loss of neurons. These morphometric changes are in turn suggestive of alterations in synaptic, dendritic and axonal organization, a view supported by immunocytochemical and ultrastructural findings. Pathology in subcortical structures is not well established, apart from dorsal thalamic nuclei, which are smaller and contain fewer neurons. Other cytoarchitectural features of
schizophrenia
which are often discussed, notably entorhinal cortex heterotopias and hippocampal neuronal disarray, remain to be confirmed. The phenotype of the affected neuronal and synaptic populations is uncertain. A case can be made for impairment of hippocampal and corticocortical excitatory pathways, but in general the relationship between neurochemical findings (which centre upon dopamine,
5-hydroxytryptamine
, glutamate and GABA systems) and the neuropathology of
schizophrenia
is unclear. Gliosis is not an intrinsic feature; its absence supports, but does not prove, the prevailing hypothesis that
schizophrenia
is a disorder of prenatal neurodevelopment. The cognitive impairment which frequently accompanies
schizophrenia
is not due to Alzheimer's disease or any other recognized neurodegenerative disorder. Its basis is unknown. Functional imaging data indicate that the pathophysiology of
schizophrenia
reflects aberrant activity in, and integration of, the components of distributed circuits involving the prefrontal cortex, hippocampus and certain subcortical structures. It is hypothesized that the neuropathological features represent the anatomical substrate of these functional abnormalities in neural connectivity. Investigation of this proposal is a goal of current neuropathological studies, which must also seek (i) to establish which of the recent histological findings are robust and cardinal, and (ii) to define the relationship of the pathological phenotype with the clinical syndrome, its neurochemistry and its pathogenesis.
...
PMID:The neuropathology of schizophrenia. A critical review of the data and their interpretation. 1021 75
During adulthood, neuronal precursor cells persist in two discrete regions, the subventricular zone and the hippocampal subgranular zone, as recently demonstrated in primates. To date, a few factors such as adrenal steroids and trophic factors are known to regulate adult neurogenesis. Since neuronal activity may also influence cellular development and plasticity in brain, we investigated the effects of serotonin depletion on cell proliferation occurring in these regions. Indeed, in addition to its role as a neurotransmitter,
5-hydroxytryptamine
(serotonin) is considered as a developmental regulatory signal. Prenatal depletion in
5-hydroxytryptamine
delays the onset of neurogenesis in
5-hydroxytryptamine
target regions and
5-hydroxytryptamine
promotes the differentiation of cortical and hippocampal neurons. Although in the adult brain, a few studies have suggested that
5-hydroxytryptamine
may play a role in neuronal plasticity by maintaining the synaptic connections in the cortex and hippocampus, no information is actually available concerning the influence of
5-hydroxytryptamine
on adult neurogenesis. If further work confirms that new neurons can be produced in the adult human brain as is the case for a variety of species, it is particularly relevant to determine the influence of
5-hydroxytryptamine
on neurogenesis in the hippocampal formation, a part of the brain largely implicated in learning and memory processes. Indeed, lack of
5-hydroxytryptamine
in the hippocampus has been associated with cognitive disorders, such as depression,
schizophrenia
and Alzheimer's disease. In the present study, we demonstrated that both inhibition of
5-hydroxytryptamine
synthesis and selective lesions of
5-hydroxytryptamine
neurons are associated with decreases in the number of newly generated cells in the dentate gyrus, as well as in the subventricular zone.
...
PMID:Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats. 1036 89
In this study, we demonstrate that clozapine and other atypical antipsychotic drugs induce a paradoxical internalization of
5-hydroxytryptamine
-2A receptors in vitro and a redistribution of
5-hydroxytryptamine
-2A receptors in vivo. We discovered that clozapine, olanzapine, risperidone and the putative atypical antipsychotic drug MDL 100,907 all induced
5-hydroxytryptamine
-2A receptor internalization in fibroblasts stably expressing the
5-hydroxytryptamine
-2A receptor in vitro. Two
5-hydroxytryptamine
-2A antagonists (mianserin and ritanserin), which have been demonstrated to reduce negative symptoms in
schizophrenia
, also caused
5-hydroxytryptamine
-2A receptor internalization. Four different drugs, each devoid of
5-hydroxytryptamine
-2A antagonist activity, had no effect on the subcellular distribution of
5-hydroxytryptamine
-2A receptors in vitro. Treatment of rats for seven days with clozapine induced an increase in intracellular
5-hydroxytryptamine
-2A receptor-like immunoreactivity in pyramidal neurons, while causing a decrease in labeling of apical dendrites in the medial prefrontal cortex. This redistribution of
5-hydroxytryptamine
-2A receptors in pyramidal neurons was also seen when rats were chronically treated with another atypical antipsychotic drug, olanzapine. The typical antipsychotic drug haloperidol, however, did not induce a redistribution of
5-hydroxytryptamine
-2A receptors in pyramidal neurons in the medial prefrontal cortex. Taken together, these results demonstrate that several atypical antipsychotic drugs with high
5-hydroxytryptamine
-2A receptor affinities induce a redistribution of
5-hydroxytryptamine
-2A receptors both in vivo and in vitro. It is conceivable that the loss of
5-hydroxytryptamine
-2A receptors from the apical dendrites of pyramidal neurons is important for the beneficial effects of atypical antipsychotic drugs and other
5-hydroxytryptamine
-2A antagonists in
schizophrenia
.
...
PMID:Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. 1036 17
The serotonergic system is known to play an important role in a number of psychiatric disorders. Indeed, treatments involving agents that have their pharmacological activities within this system are the mainstay of treatment for disorders such as
schizophrenia
. It is now widely accepted that many common psychiatric disorders have a familial or genetic component and as a result of this there has been an upsurge in interest in the
5-hydroxytryptamine
(
5-HT
) pathways. A number of groups have attempted to establish whether polymorphism in particular proteins of the serotonergic system may form part of the genetic component of psychiatric disorders, including
schizophrenia
and anorexia nervosa. However, the data from these studies are conflicting and the problem is compounded by the lack of known polymorphic genetic markers mapping in close proximity to genes encoding proteins envolved directly or indirectly in
5-HT
neurotransmission. In the current study, we have fine mapped the gene for 5-HTR2a by radiation hybrid mapping, and we report two new, highly linked, polymorphic markers that are suitable for linkage and association studies.
...
PMID:Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders. 1046 62
In prefrontal cortex,
5-hydroxytryptamine
(2A) (5-HT(2A)) receptors have been linked to the action of hallucinogens and atypical antidepressant/antipsychotic drugs. Previously, we have shown in cortical layer V pyramidal cells that a nonselective metabotropic glutamate (mGlu) receptor agonist suppresses the induction of excitatory postsynaptic potentials/currents (EPSPs/EPSCs) via activation of 5-HT(2A) receptors. In this study, we tested the ability of the selective mGlu2/3 agonist (1S,2S,5R, 6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate (LY354740) and the selective mGlu2/3 antagonist 2S-2-amino-2-(1S, 2S-2-carboxycycloprop-1-yl)-3(xanthy-9-yl)propanoic acid (LY341495) to modulate serotonin(5-HT)-induced EPSPs and electrically evoked EPSPs by using intracellular recording from layer V pyramidal cells in medial prefrontal cortex. The mGlu2/3 antagonist LY341495 increased the frequency and amplitude of 5-HT-induced EPSCs, suggesting a role for mGlu2/3 receptors in mediating the action of endogenous glutamate on autoreceptors. Conversely, the mGlu2/3 agonist LY354740 was highly effective and potent (EC(50) = 89 nM) in suppressing glutamate release induced by 5-HT(2A) receptor activation in the medial prefrontal cortex, probably via a presynaptic mechanism. The mGlu2/3 antagonist LY341495 potently blocked the suppressant effect of LY354740 on 5-HT-induced EPSCs as well as electrically evoked early EPSPs. Autoradiography with the radioligands [(3)H]LY354740 and [(125)I](+/-)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane showsa striking overlap of the laminar distribution of mGlu2/3 and 5-HT(2A) receptors in the medial prefrontal cortex that is not apparent in other cortical regions. These findings suggest a close coupling between mGlu2/3 and 5-HT(2A) receptors in the prefrontal cortex that may be relevant for novel therapeutic approaches in the treatment of neuropsychiatric syndromes such as depression and
schizophrenia
.
...
PMID:Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. 1060 33
Aromatic L-amino acid decarboxylase (AADC) is a relatively non specific enzyme involved in the biosynthesis of several classical neurotransmitters including dopamine and
5-hydroxytryptamine
(5HT; serotonin). AADC does not catalyse the rate limiting step in either pathway, but is rate limiting in the synthesis of 2-phenylethylamine (2PE) which is a positive modulator of dopaminergic transmission and a candidate natural psychotogenic compound.1 We and others have proposed that polymorphism in AADC resulting in altered 2PE activity might contribute to the pathogenesis of psychosis. In order to test this hypothesis, we have used denaturing high performance liquid chromatography (DHPLC)3 to screen 3943 bases of the AADC gene and its promoter regions for variants that might affect protein structure or expression in 15 unrelated people with
schizophrenia
, and 15 unrelated people with bipolar disorder. Three polymorphisms were identified by DHPLC: a insertion/deletion polymorphism in the 5' UTR of the neuronal specific mRNA (g.-33-30delAGAG, bases 586-589 of GenBank M77828), a T>A variant in the non-neuronal exon 1 (g. -67T>A, GenBank M88070), and a G>A polymorphism within intron 8 (g. IVS8 +75G>A, GenBank M84598). Case-control analysis did not suggest that genetic polymorphism in the AADC gene is associated with liability for developing
schizophrenia
or bipolar disorder.
...
PMID:Comparative sequencing and association studies of aromatic L-amino acid decarboxylase in schizophrenia and bipolar disorder. 1088 38
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>